Hematology NewsPriority review granted to lenalidomide for FL, MZLMarch 2, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersAggressive Lymphomas
Oncology PracticeBarriers to CAR T use in the spotlight at first European meetingFebruary 28, 2019Immuno-oncologyImmunotherapyB Cell LymphomaAggressive LymphomasCellular TherapyBusiness of MedicineGene Therapy
Hematology TimesResearchers characterize new subtype of high-grade DLBCLFebruary 17, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology NewsFew DLBCL patients benefit from nivolumabFebruary 14, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsAnthracyclines, bendamustine are options for grade 3A follicular lymphomaFebruary 11, 2019Follicular LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsIbrutinib-MTX-rituximab combo shows promise in CNS lymphomaFebruary 11, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersCNS/Brain CancerB Cell Lymphoma
Hematology TimesApplying ECHELON-2 results to clinical practiceJanuary 31, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersT Cell Lymphomas
Hematology NewsNovel bispecific CAR shows promise in B-cell malignanciesJanuary 25, 2019Aggressive LymphomasCellular TherapyLymphoma & Plasma Cell DisordersTransplantationImmuno-oncologyImmunotherapyB Cell Lymphoma
Hematology NewsImaging, radiotherapy clarified in new PMBCL guidelinesJanuary 25, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology TimesCombo treatment may improve quality of life in CTCLJanuary 24, 2019T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology TimesAre single agents better than chemo for relapsed/refractory PTCL?January 24, 2019Lymphoma & Plasma Cell DisordersAggressive LymphomasT Cell Lymphomas
Hematology TimesFour-drug combo shows durable responses in relapsed/refractory lymphomasJanuary 19, 2019T Cell LymphomasAggressive LymphomasB Cell Lymphoma
Hematology NewsZanubrutinib receives breakthrough designation for MCLJanuary 18, 2019Mantle Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology TimesChidamide may be more effective in PTCL than previously thoughtJanuary 16, 2019T Cell LymphomasAggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsAdding umbralisib to ibrutinib produced responses in MCL, CLLJanuary 10, 2019CLLMantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
